Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
NCT04291105 · View on ClinicalTrials.gov ↗
Study Summary
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are progressing on CPI treatment.
Conditions Studied
Interventions
- BIOLOGICAL Cemiplimab
- BIOLOGICAL VV1
Study Locations (20)
California
- City of Hope Medical Center — Durate
- USC Norris Comprehensive Cancer Center — Los Angeles
- HOAG Memorial Hospital Presbyterian — Newport Beach
- Saint John's Health Center - John Wayne Cancer Institute (JWCI) — Santa Monica
- Stanford Health Care — Stanford
Florida
- Mayo Clinical — Jacksonville
- University of Miami — Miami
Minnesota
- Masonic Cancer Center, University of Minnesota — Minneapolis
- Mayo Clinic — Rochester
New Jersey
- Atlantic Health — Morristown
- Rutgers Cancer Institute of New Jersey — New Brunswick
Ohio
- University of Cincinnati Medical Center — Cincinnati
- Ohio State University — Columbus
Arizona
- Mayo Clinical — Phoenix
Connecticut
- Yale University — New Haven
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2020-04-24 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04291105
The ClinicalTrials.gov registry entry for NCT04291105 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyriad, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions — of which Cemiplimab is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT04291105 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT04291105 about?
NCT04291105 is a clinical study titled "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients". This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separate tumor cohorts. The cancers types are colorectal, head and neck carcinoma, and melanoma that are ...
What is the current status of trial NCT04291105?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 87 participants. The study started on 2020-04-24. Estimated completion is 2025-12.
What conditions does trial NCT04291105 study?
This clinical trial studies the following conditions: Melanoma, Head and Neck Squamous Cell Carcinoma, Colo-rectal Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT04291105?
The interventions under investigation include: Cemiplimab (BIOLOGICAL), VV1 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT04291105?
This trial is sponsored by Vyriad, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT04291105 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.